The Lancet Gastroenterology & Hepatology
Fecha de publicación: 29 March 2018
DOI: https://doi.org/10.1016/S2468-1253(18)30116-X
Autores: Stefanos Bonovas, Laurent Peyrin-Biroulet, Silvio Danese
Background: Biological therapies have advanced treatment of inflammatory bowel disease. However, their high costs are challenging the sustainability of health-care systems. As the patents of older biological drugs have expired, copy versions of the innovator molecules (ie, biosimilars) have started to receive marketing authorisations, thus offering a potential way to reduce health-care spending and increase treatment access.
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.